AgeX Therapeutics appoints Steven Mintz to Board of Directors, effective Jan 8, 2024

Serina Therapeutics, Inc.

Board of Directors expanded to four members; Steven Mintz appointed as director effective Jan 8, 2024.
Mintz serves on Audit, Compensation, and Nominating committees. He is a financial consultant and director at Portage Biotech.
Receives cash fee of $34,331 and options to purchase 63,756 shares of AgeX common stock for 2024 service.
Additional cash fee of $9,809 for Audit Committee chair role. Fees and options vest quarterly through Dec 31, 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven Mintz

Director

SER · Serina Therapeutics, Inc.

Effective: 2024-01-08
Filed: January 11, 2024, 6:59 PM ET

On January 8, 2024, the AgeX Board of Directors increased the size of the Board of Directors (the “Board”) to four directors and appointed Steven Mintz as a director to fill the new vacancy on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Steven Mintz was appointed as Director at Serina Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 8, 2024, the AgeX Board of Directors increased the size of the Board of Directors (the “Board”) to four directors and appointed Steven Mintz as a director to fill the new vacancy on the Board.

View on SEC.gov

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-002061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.